Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 118, Issue 9, Pages -Publisher
NATL ACAD SCIENCES
DOI: 10.1073/pnas.2018342118
Keywords
C. elegans; muscle; mitochondria; hydrogen sulfide; mouse
Categories
Funding
- University of Nottingham School of Medicine
- Fulbright U.S. Student Program
- Germanistic Society of America
- Medical Research Council (MRC) [MR/T026014/1]
- NASA [NNX15AL16G]
- Biotechnology and Biological Sciences Research Council [BB/N015894/1]
- MRC [MR/5002626/1]
- United Mitochondrial Disease Foundation [PI -19-0985]
- Brian Ridge Scholarship
- University of Exeter Diamond Jubilee Scholarship
- MRC Versus Arthritis Centre for Musculoskeletal Ageing Research Grants [MR/P021220/1, MR/R502364/1]
- National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre
- Graham Painton Foundation Fellowship from University of New South Wales Sydney
- McKenzie Research Fellowship from The University of Melbourne
- National Health and Medical Research Council [GNT1124474]
- Rebecca L. Cooper Medical Research Foundation
- Osteopathic Heritage Foundation
- MRC [MR/S002626/1, MR/T026014/1, MR/P021220/1] Funding Source: UKRI
- NASA [NNX15AL16G, 807298] Funding Source: Federal RePORTER
Ask authors/readers for more resources
Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by muscle degeneration and weakness. Recent studies have shown that hydrogen sulfide (H2S) supplementation may improve muscle function and metabolism, suggesting a potential therapeutic approach for DMD. Deficits in H2S may contribute to DMD pathology, and delivery of H2S compounds could be a promising treatment strategy.
Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder characterized by progressive muscle degeneration and weakness due to mutations in the dystrophin gene. The symptoms of DMD share similarities with those of accelerated aging. Recently, hydrogen sulfide (H2S) supplementation has been suggested to modulate the effects of age-related decline in muscle function, and metabolic H2S deficiencies have been implicated in affecting muscle mass in conditions such as phenylketonuria. We therefore evaluated the use of sodium GYY4137 (NaGYY), a H2S-releasing molecule, as a possible approach for DMD treatment. Using the dys-1(eg33) Caenorhabditis elegans DMD model, we found that NaGYY treatment (100 mu M) improved movement, strength, gait, and muscle mitochondrial structure, similar to the gold-standard therapeutic treatment, prednisone (370 mu M). The health improvements of either treatment required the action of the kinase JNK-1, the transcription factor SKN-1, and the NAD-dependent deacetylase SIR-2.1. The transcription factor DAF-16 was required for the health benefits of NaGYY treatment, but not prednisone treatment. AP39 (100 pM), a mitochondria-targeted H2S compound, also improved movement and strength in the dys-1(eg33) model, further implying that these improvements are mitochondria-based. Additionally, we found a decline in total sulfide and H2S-producing enzymes in dystrophin/utrophin knockout mice. Overall, our results suggest that H2S deficit may contribute to DMD pathology, and rectifying/overcoming the deficit with H2S delivery compounds has potential as a therapeutic approach to DMD treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available